Article
Abolishing respiratory complex I decreases in vivo growth of high grade serous ovarian cancer cells and sensitizes to anti-angiogenic therapy
2026-03-03
Abstract excerpt
Targeting mitochondrial Complex I (CI) is a currently emerging anti-cancer strategy, with several enzyme inhibitors entering clinical trials. Among others, aggressive high-grade serous tubo-ovarian cancer (HGSOC) may particularly benefit from this therapeutic approach due to the scarce response to first- and second-line treatments, with consequent high mortality, such as the anti-angiogenic bevacizumab. We here sh...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 77b0bc52-f2e4-555c-82dc-f3539ba5bf2a
- DOI
- 10.64898/2026.02.28.708681
